For research purposes only. This content is intended for scientific and educational reference. Not intended for human use or as medical advice.
Introduction
CJC-1295 and Ipamorelin are two distinct synthetic peptides that target separate components of the growth hormone (GH) secretion pathway. In preclinical and clinical research, these compounds are frequently studied in combination because their mechanisms of action are complementary — CJC-1295 stimulates GH release through the GHRH receptor, while Ipamorelin mimics ghrelin to activate the GH secretagogue receptor (GHSR). Together, they engage two independent signaling pathways that converge on pituitary somatotroph cells to produce GH.
This dual-pathway approach places CJC-1295/Ipamorelin research within the broader context of GH secretagogue pharmacology, alongside FDA-approved compounds such as Tesamorelin, which similarly targets the GHRH receptor but in a single-agent framework. For researchers studying the comparative pharmacology of GH axis modulation, the CJC-1295/Ipamorelin combination represents a well-characterized dual-stimulation model.
CJC-1295: Mechanism of Action
Structure and Stability
CJC-1295 is a synthetic GHRH analog consisting of the first 29 amino acids of endogenous GHRH with several amino acid substitutions to improve stability. The most widely studied form — CJC-1295 with DAC (Drug Affinity Complex) — incorporates a lysine-maleimidoproprionic acid modification that enables covalent binding to circulating albumin, dramatically extending its half-life from minutes (endogenous GHRH) to several days.
A non-DAC variant (sometimes referred to as Modified GRF 1-29) lacks this albumin-binding modification and has a shorter active window more closely resembling physiological GHRH pulses.
GHRH Receptor Agonism
Like Tesamorelin, CJC-1295 binds to and activates the GHRH receptor on anterior pituitary somatotroph cells, stimulating the synthesis and pulsatile release of endogenous growth hormone. The GH released subsequently acts on the liver and peripheral tissues to stimulate IGF-1 production, driving the downstream anabolic and metabolic effects associated with GH axis activity.
Published Clinical Data
Ionescu M and Frohman LA — Journal of Clinical Endocrinology & Metabolism, 2006
A Phase 1/2 clinical study examined CJC-1295 in healthy adults, reporting:
- Dose-dependent increases in GH levels following administration
- Sustained elevation of IGF-1 over multiple days with the DAC-modified form
- A generally well-tolerated adverse event profile at studied doses
- GH release patterns consistent with amplified pulsatile secretion rather than continuous elevation
Ipamorelin: Mechanism of Action
Structure and Classification
Ipamorelin is a synthetic pentapeptide (5 amino acids) and a member of the growth hormone releasing peptide (GHRP) class. It functions as a selective ghrelin receptor agonist, binding to the growth hormone secretagogue receptor (GHSR-1a) expressed on pituitary somatotrophs and hypothalamic neurons.
Selectivity Profile
Ipamorelin is notable within the GHRP class for its high selectivity. Unlike earlier GHRPs such as GHRP-2 and GHRP-6, Ipamorelin demonstrates minimal stimulation of cortisol (ACTH) and prolactin secretion at research-relevant doses in animal models. This selectivity has made it a preferred compound for studies where isolated GH axis stimulation is desired without concurrent activation of other pituitary axes.
Ghrelin Receptor Agonism
By activating GHSR-1a, Ipamorelin triggers intracellular calcium release and protein kinase C activation in somatotroph cells, stimulating GH secretion through a pathway entirely distinct from GHRH receptor signaling. This mechanistic independence is the pharmacological rationale for combining Ipamorelin with GHRH analogs in research settings.
Raun K, et al. — European Journal of Endocrinology, 1998
The foundational preclinical study characterizing Ipamorelin in rats demonstrated:
- Potent, dose-dependent GH release comparable to GHRP-6
- Significantly lower cortisol and prolactin stimulation than GHRP-2 or GHRP-6
- Maintained GH pulsatility consistent with physiological patterns
The Combination Rationale: Why These Two Compounds Are Studied Together
The scientific rationale for studying CJC-1295 and Ipamorelin in combination derives from their distinct and synergistic mechanisms:
- CJC-1295 acts on the GHRH receptor, amplifying the magnitude of GH pulses
- Ipamorelin acts on the ghrelin receptor (GHSR), increasing GH pulse frequency and sensitizing somatotrophs to GHRH stimulation
Research in rodent models has demonstrated that combined GHRH/GHRP administration produces synergistic GH release — substantially greater than either compound alone — through what researchers have termed “somatotroph priming.” This synergy has made the combination a standard model for studying maximal physiological GH secretion in preclinical settings.
Key Research Areas
Body Composition Research
The GH/IGF-1 axis plays a central role in regulating the ratio of lean mass to adipose tissue. Preclinical and early clinical research on CJC-1295 and related GHRH analogs has examined effects on:
- Lean body mass maintenance in aging models
- Visceral and subcutaneous adipose tissue reduction
- Muscle protein synthesis rates
Bone Density Research
GH and IGF-1 are established regulators of bone metabolism. Research models examining GHRH analog and GHRP combinations have investigated their effects on bone mineral density markers, particularly in aged animal models where GH secretion is naturally reduced.
Sleep Architecture
GH secretion is closely linked to slow-wave sleep, with the largest endogenous GH pulse occurring shortly after sleep onset. Research examining GHRH analogs and GHRPs has explored the relationship between GH secretagogue activity and sleep quality parameters in animal models, an area of growing interest given the role of GH in tissue repair during sleep.
Comparison to Related Research Compounds
| Compound | Class | Receptor Target | Half-life | Selectivity |
|---|---|---|---|---|
| CJC-1295 (DAC) | GHRH analog | GHRHR | ~6–8 days | GHRH pathway only |
| Ipamorelin | GHRP | GHSR-1a | ~2 hours | High GH selectivity |
| Tesamorelin | GHRH analog | GHRHR | ~26 minutes | GHRH pathway only |
| Sermorelin | GHRH analog | GHRHR | ~10–20 minutes | GHRH pathway only |
Research Status
Neither CJC-1295 nor Ipamorelin has received FDA approval for any indication. Both remain investigational compounds. CJC-1295 has completed Phase 1/2 clinical evaluation; Ipamorelin has been evaluated in preclinical models and early-phase human studies. Neither has progressed to Phase 3 trials as standalone agents.
Both compounds are available as research-grade peptides for laboratory use.
Research Applications
Current areas of scientific investigation include:
- Dual-pathway GH secretagogue pharmacology
- GH/IGF-1 axis modulation in aging models
- Body composition and lean mass research
- Bone metabolism in GH-deficient animal models
- Sleep and GH secretion relationship studies
- Comparative GHRH analog research (with Tesamorelin and Sermorelin)
References
- Ionescu M, Frohman LA. “Pulsatile Secretion of Growth Hormone (GH) Persists During Continuous Stimulation by CJC-1295, a Long-Acting GH-Releasing Hormone Analog.” Journal of Clinical Endocrinology & Metabolism. 2006;91(12):4792–4797. PubMed
- Raun K, et al. “Ipamorelin, the first selective growth hormone secretagogue.” European Journal of Endocrinology. 1998;139(5):552–561. PubMed
- Svensson J, et al. “Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure.” Journal of Clinical Endocrinology & Metabolism. 1998;83(2):362–369. PubMed
- Arvat E, et al. “Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone.” Journal of Clinical Endocrinology & Metabolism. 2001;86(3):1169–1174. PubMed
- Alba M, et al. “Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.” American Journal of Physiology Endocrinology and Metabolism. 2006;291(6):E1290–E1294. PubMed
Pure Research Peptides LLC supplies research-grade CJC-1295 and Ipamorelin with third-party verified purity (≥99%) and Certificate of Analysis documentation. All products are intended for laboratory and research use only.